Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

James R Berenson, MD, To Jennifer, BS, Tanya M. Spektor, PhD, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Alberto Bessudo, MD, Ravindranath Patel, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2018) 132 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2018-99-119274

Published: 2018

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael Harb, Hui Yang, Dawn Pinchasik, Amy S. Kimball, James R. Berenson, MD

Blood (2016) 128 (22): 3325.

https://doi.org/10.1182/blood.V128.22.3325.3325

Published: 2016

Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja

Blood (2016) 127 (26): 3360–3368.

https://doi.org/10.1182/blood-2015-11-683854

Published: 2016

Includes: Supplemental data

Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 4074.

https://doi.org/10.1182/blood.V126.23.4074.4074

Published: 2015

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Rasim Gucalp, MD, Karl Insogna, MD, Mimi Hu, MD, Ilya Glezerman, MD, Sophie Leboulleux, MD, Waldemar Misiorowski, MD, Bennett Yu, MD, Paul Zorsky, MD, Diego Tosi, MD, Alberto Bessudo, MD, Arnaud Jaccard, MD, Giuseppe Tonini, MD, Wendy Ying, PhD, Ada H. Braun, MD, PhD, Rajul K. Jain, MD

Blood (2013) 122 (21): 2536.

https://doi.org/10.1182/blood.V122.21.2536.2536

Published: 2013

Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2013) 122 (21): 3218.

https://doi.org/10.1182/blood.V122.21.3218.3218

Published: 2013

Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 4063.

https://doi.org/10.1182/blood.V120.21.4063.4063

Published: 2012

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Katherine Sue Robinson, MD, Michael E. Williams, MD, Philip Cohen, MD, Anil Tulpule, MD, Richard H. van der Jagt, MD, Jordan A. Herst, MD, Robin M. Joyce, MD, Alberto Bessudo, MD, Bernard Lemieux, MD, Lee S. Schwartzberg, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 923.

https://doi.org/10.1182/blood.V106.11.923.923

Published: 2005

Journal Articles

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

Jonathan W. Friedberg, MD, Philip Cohen, MD, Bruce D. Cheson, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Luis Fayad, MD, Ann S. La Casce, MD, Alberto Bessudo, MD, Elber S. Camacho, MD, Michael E. Williams, MD, Richard H. van der Jagt, MD, Jennifer Oliver, MD, Ely Benaim, MD

Blood (2005) 106 (11): 229.

https://doi.org/10.1182/blood.V106.11.229.229

Published: 2005

Journal Articles

A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.

James Berenson, Ralph Boccia, David Siegel, Marek Bozdech, Alberto Bessudo, Edward Stadtmauer, J. Talisman Pomeroy, Ronald Steis, Marshall Flam, Jose Lutzky, Syed Jilani, Joseph Volk, Tiberio Lindgren, Robert Moss, Ravi Patel, Delina Ferreti, Howard Yeh, Sal Bevivino

Blood (2005) 106 (11): 2564.

https://doi.org/10.1182/blood.V106.11.2564.2564

Published: 2005

Journal Articles

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Alberto Bessudo, Laura Rassenti, Diane Havlir, Douglas Richman, Ellen Feigal, Thomas J. Kipps

Blood (1998) 92 (4): 1317–1323.

https://doi.org/10.1182/blood.V92.4.1317

Published: 1998

NARROW

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

Bendamustine HCl (TREANDA TM ) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).

A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma.

Aberrant and Unstable Expression of Immunoglobulin Genes in Persons Infected With Human Immunodeficiency Virus

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only